The effect of glucagon-like peptide-1 in the management of diabetes mellitus: cellular and molecular mechanisms

Cell and Tissue Research

Volumn 358, Issue 2, 2014, Pages 343-358

  Lotfy, Mohamed ^a,b,c   Singh, Jaipaul ^c   Rashed, Hameed ^d   Tariq, Saeed ^d   Zilahi, Erika ^d   Adeghate, Ernest ^d  

^a UNITED ARAB EMIRATES UNIVERSITY   (United Arab Emirates)

^b NATIONAL RESEARCH CENTRE   (Egypt)

^c UNIVERSITY OF CENTRAL LANCASHIRE   (United Kingdom)

^d UNITED ARAB EMIRATES UNIVERSITY   (United Arab Emirates)

Author keywords

Diabetes mellitus; Exenatide; Gene expression; GLP 1; Glucagon; Glucose; Insulin; Rats; Streptozotocin

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CATALASE; EXENDIN 4; GLUCAGON; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; GLUCOSE; GLUTATHIONE PEROXIDASE; GLUTATHIONE REDUCTASE; HEAT SHOCK PROTEIN 70; INSULIN; INSULIN RECEPTOR; UREA; URIC ACID; GLUCOSE BLOOD LEVEL; LIPID; PEPTIDE; VENOM;

ACTB GENE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; ENZYME LINKED IMMUNOSORBENT ASSAY; GCG GENE; GENE; GENE EXPRESSION; GLP 1R GENE; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE TEST; GPX GENE; HSP 70 GENE; IMMUNOCOMPETENT CELL; IMMUNOELECTRON MICROSCOPY; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; INSR GENE; INSULIN BLOOD LEVEL; INSULIN RELEASE; KIDNEY FUNCTION; LIPID ANALYSIS; LIVER FUNCTION; MALE; NONHUMAN; PANCREAS ISLET BETA CELL; PDX 1 GENE; RAT; REAL TIME POLYMERASE CHAIN REACTION; STREPTOZOTOCIN-INDUCED DIABETES MELLITUS; UREA NITROGEN BLOOD LEVEL; WEIGHT REDUCTION; ANIMAL; BLOOD; BODY WEIGHT; DIABETES MELLITUS, EXPERIMENTAL; DRUG EFFECTS; ENZYMOLOGY; FLUORESCENT ANTIBODY TECHNIQUE; GENE EXPRESSION REGULATION; GENETICS; KIDNEY; LIVER; METABOLISM; PANCREAS ISLET; PATHOLOGY; PATHOPHYSIOLOGY; SECRETION (PROCESS); TIME; ULTRASTRUCTURE; WISTAR RAT;

ANIMALS; BLOOD GLUCOSE; BODY WEIGHT; CATALASE; DIABETES MELLITUS, EXPERIMENTAL; FLUORESCENT ANTIBODY TECHNIQUE; GENE EXPRESSION REGULATION; GLUCAGON; GLUCAGON-LIKE PEPTIDE 1; GLUCOSE TOLERANCE TEST; GLUTATHIONE REDUCTASE; INSULIN; ISLETS OF LANGERHANS; KIDNEY; LIPIDS; LIVER; MALE; PEPTIDES; RATS, WISTAR; TIME FACTORS; VENOMS;

EID: 84919946463     PISSN: 0302766X     EISSN: 14320878     Source Type: Journal    
DOI: 10.1007/s00441-014-1959-9     Document Type: Article

References (62)

1. Adeghate E (1999) Effect of subcutaneous pancreatic tissue transplants on streptozotocin-induced diabetes in rats. I. Morphological studies on normal, diabetic and transplanted pancreatic tissues. Tissue Cell 31:66–72
2. Adeghate E, Ponery AS (2002) Ghrelin stimulates insulin secretion from the pancreas of normal and diabetic rats. J Neuroendocrinol 14:555–560
3. Adeghate E, Ponery AS (2004) Diabetes mellitus influences the degree of co-localization of calcitonin-gene-related-peptide with insulin and somatostatin in the rat pancreas. Pancreas 29:311–319
4. Amin A, Lotfy M, Mahmoud-Ghoneim D, Adeghate E, Al-Akhras MA, Al-Saadi M, Al-Rahmoun S, Hameed R (2011) Pancreas-protective effects of chlorella in STZ-induced diabetic animal model: insights into the mechanism. J Diabetes Mellit 1(3):36–45
5. Aragon G, Younossi ZM (2010) When and how to evaluate mildly elevated liver enzymes in apparently healthy patients. Cleve Clin J Med 77(3):195–204
6. Baggio LL, Drucker DJ (2007) Biology of incretins: GLP-1 and GIP. Gastroenterol 132:2131–2157
7. Bener A, Zirie M, Janahi IM, Al-Hamaq AO, Musallam M, Wareham NJ (2009) Prevalence of diagnosed and undiagnosed diabetes mellitus and its risk factors in a population-based study of Qatar. Diabetes Res Clin Pract 84(1):99–106
8. Bouwens L, Rooman I (2005) Regulation of pancreatic beta-cell mass. Physiol Rev 85(4):1255–1270
9. Bucinskaite V, Tolessa T, Pedersen J, Rydqvist B, Zerihun L, Holst JJ, Hellström PM (2009) Receptor-mediated activation of gastric vagal afferents by glucagon-like peptide-1 in the rat. J Neurogastroenterol Motil 21:978–978
10. Bulchandani D, Nachnani J, Eaton C, Hamburg M (2009) Association of Exenatide with liver enzymes in patients with type 2 diabetes. Curr Opin Endocrinol Diabetes Obes 19(3):114–115
11. Buse JB, Rosenstock J, Sesti G, Schmidt WE, Montanya E, Brett JH, Zychma M, Blonde L (2009) Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet 374(4):39–47
12. Buteau J, El-Assaad W, Rhodes CJ, Rosenberg L, Joly E, Prentki M (2004) Glucagon-like peptide-1 prevents beta cell glucolipotoxicity. Diabetologia 47:806–815
13. Caluwaerts S, Lambin S, van Bree R, Peeters H, Vergote I, Verhaeghe J (2007) Diet-induced obesity in gravid rats engenders early hyperadiposity in the offspring. Metabolism 56:1431–1438
14. Cejkova P, Fojtikova M, Cerna M (2009) Immunomodulatory role of prolactin in diabetes development. Autoimmun Rev 9(1):23–27
15. Cernea S, Raz I (2011) Therapy in the early stage: incretins. Diabetes Care 34(2):S264–S271
16. Druker DJ (2005) Therapeutic strategic based on GLP-1 pathway. Adv Stud Med 5(10E):S1069–S1073
17. Fehmann HC, Hering BJ, Wolf MJ, Brandhorst H, Brandhorst D, Bretzel RG, Federlin K, Göke B (1995) The effects of glucagon-like peptide-I (GLP-I) on hormone secretion from isolated human pancreatic islets. Pancreas 11:196–200
18. Fisher TL, White MF (2004) Signaling pathways: the benefits of good communication. Curr Biol 14:R1005–R1007
19. Fujita A, Sasaki H, Ogawa K, Okamoto K, Matsuno S, Matsumoto E, Furuta H, Nishi M, Nakao T, Tsuno T, Taniguchi H, Nanjo K (2005) Increased gene expression of antioxidant enzymes in KKAy diabetic mice but not in STZ diabetic mice. Diabetes Res Clin Pract 69(2):113–119
20. Garber AJ (2011) Incretin effects on β-cell function, replication, and mass. Diabetes Care 34(2):S258–S263
21. Gezginci-Oktayoglu S, Bolkent S (2009) Exendin-4 exerts its effects through the NGF/p75NTR system in diabetic mouse pancreas. Biochem Cell Biol 87(4):641–651
22. Girard J (2008) The incretins: from the concept to their use in the treatment of type 2 diabetes. Part A: incretins: concept and physiological functions. Diabetes Metab 34:550–559
23. Habib AM, Richards P, Rogers GJ, Reimann F, Gribble FM (2013) Co-localisation and secretion of glucagon-like peptide 1 and peptide YY from primary cultured human L cells. Diabetologia 56:1413–1416
24. Hamouchene H, Arlt VM, Giddings I, Phillips DH (2011) Influence of cell cycle on responses of MCF-7 cells to benzo[a]pyrene. BMC Med Genom 12:333
25. Hare KJ, Vilsbøll T, Asmar M, Deacon CF, Knop FK, Holst JJ (2010) The glucagonostatic and insulinotropic effects of glucagon-like peptide 1 contribute equally to its glucose-lowering action. Diabetes 59:1765–1770
26. Heller RS, Kieffer TJ, Habener JF (1997) Insulinotropic glucagon-like peptide I receptor expression in glucagon-producing alpha-cells of the rat endocrine pancreas. Diabetes 46(5):785–791
27. Holst JJ (2008) The physiology and pharmacology of incretins in type 2 diabetes mellitus. Diabetes Obes Metab 10:14–21
28. Hutt DM, Powers ET, Balch WE (2009) The proteostasis boundary in misfolding diseases of membrane traffic. FEBS Lett 583:2639–2646
29. Islam MS (2010) Calcium signaling in the islets. Adv Exp Med Biol 654:235–259
30. Kanitkara M, Bhonde RR (2008) Curcumin treatment enhances islet recovery by induction of heat shock response proteins, Hsp70 and heme oxygenase-1, during cryopreservation. Life Sci 82(3–4):182–189
31. Karaca M, Magnan C, Kargar C (2009) Functional pancreatic beta-cell mass: involvement in type 2 diabetes and therapeutic intervention. Diabetes Metab 35:77–84
32. Kawahito S, Kitahata H, Oshita S (2009) Problems associated with glucose toxicity: role of hyperglycemia-induced oxidative stress. World J Gastroenterol 15(33):4137–4142
33. Kitamura T, Kahn CR, Accili D (2003) Insulin receptor knockout mice. Annu Rev Physiol 65:313–332
34. Kjems LL, Holst JJ, Vølund A, Madsbad S (2003) The influence of GLP-1 on glucose-stimulated insulin secretion: effects on beta-cell sensitivity in type 2 and nondiabetic subjects. Diabetes 52:380–386
35. Kumar PJ, Clark ML (2007) Diabetes mellitus and other disorders of metabolism. In: Kumar PJ, Clark ML (eds) Clinical medicine, 6th edn. Saunders, London, pp 1069–1121
36. Larsen MO (2009) Beta-cell function and mass in type 2 diabetes. Dan Med J 56:153–164
37. Leibiger B, Leibiger IB, Moede T, Kemper S, Kulkarni RN, Kahn CR, de Vargas LM, Berggren P-O (2001) Selective insulin signaling through A and B insulin receptors regulates transcription of insulin and glucokinase genes in pancreatic beta cells. Mol Cell 7(3):559–570
38. Liu Q, Adams L, Broyde A, Fernandez R, Baron AD, Parkes DG (2010) The exenatide analogue AC3174 attenuates hypertension, insulin resistance, and renal dysfunction in Dahl salt-sensitive rats. Cardiovasc Diabetol 9(32):1–10
39. Lotfy M, Singh J, Rashed H, Tariq S, Zilahi E, Adeghate E (2014) Mechanism of the beneficial and protective effects of exenatide in diabetic rats. J Endocrinol 220(3):291–304
40. Mayhew TM, Lucocq JM (2011) Multiple-labelling immunoEM using different sizes of colloidal gold: alternative approaches to test for differential distribution and colocalization in subcellular structures. Histochem Cell Biol 135:317–326
41. Montrose-Rafizadeh C, Wang Y, Janczewski AM, Henderson TE, Egan JM (1997) Overexpression of glucagon-like peptide-1 receptor in an insulin-secreting cell line enhances glucose responsiveness. Mol Cell Endocrinol 130(1–2):109–117
42. Mudaliar S, Henry RR (2010) Effects of incretin hormones on β-cell mass and function, body weight, and hepatic and myocardial function. Am J Med 123(3):S19–S27
43. Park S, Dong X, Fisher TL, Dunn S, Omer AK, Weir G, White MF (2006) Exendin-4 uses Irs2 signaling to mediate pancreatic beta cell growth and function. J Biol Chem 281(2):1159–1168
44. Patel SK, Goyal RK, Anand IS, Shah JS, Patel HU, Patel CN (2006) Glucagon like peptide-1: a new therapeutic target for diabetes mellitus. Indian J Pharmacol 38(4):231–237
45. Perfeitti R, Zhou J, Doyle ME, Egan J (2000) Glucagon-like peptide-1 induces cell proliferation and pancreatic-duodenum homeobox-1 expression and increases endocrine cell mass in the pancreas of old, glucose-intolerant rats. Endocrinol 141(12):4600–4605
46. Portha B, Tourrel-Cuzin C, Movassat J (2011) Activation of the GLP-1 receptor signalling pathway: a relevant strategy to repair a deficient beta-cell mass. Exp Diabetes Res 2011:376509
47. Puddu A, Mach F, Nencioni A, Viviani GL, Montecucco F (2013) An emerging role of glucagon-like peptide-1 in preventing advanced-glycation-end-product-mediated damages in diabetes. Mediat Inflamm 2013:591056
48. Robertson RP, Harmon JS (2007) Pancreatic islet β-cell and oxidative stress: the importance of glutathione peroxidase. FEBS Lett 581:3743–3748
49. Romaní-Pérez M, Outeiriño-Iglesias V, Gil-Lozano M, González-Matías LC, Mallo F, Vigo E (2013) Pulmonary GLP-1 receptor increases at birth and exogenous GLP-1 receptor agonists augmented surfactant-protein levels in litters from normal and nitrofen-treated pregnant rats. Endocrinol 154(3):1144–1155
50. Salehi M, Aulinger BA, D’Alessio DA (2008) Targeting β-cell mass in type 2 diabetes: promise and limitations of new drugs based on incretins. Endocr Rev 29(3):367–379
51. Schwartz EA, Koska J, Mullin MP, Syoufi I, Schwenke DC, Reaven PD (2010) Exenatide suppresses postprandial elevations in lipids and lipoproteins in individuals with impaired glucose tolerance and recent onset type 2 diabetes mellitus. Atherosclerosis 212(1):217–222
52. Shu T, Zhu Y, Wang H, Lin Y, Ma Z, Han X (2011) AGEs decrease insulin synthesis in pancreatic β-cell by repressing Pdx-1 protein expression at the post-translational level. PLoS ONE 6(4):e18782
53. Song WJ, Seshadri M, Ashraf U, Mdluli T, Mondal P, Keil M, Azevedo M, Kirschner LS, Stratakis CA, Hussain MA (2011) Snapin mediates incretin action and augments glucose-dependent insulin secretion. Cell Metab 13(3):308–319
54. Srinivasan K, Ramarao P (2007) Animal models in type 2 diabetes research: an overview. Indian J Med Res 125:451–472
55. Stanley S, Wynne K, McGowan B, Bloom S (2005) Hormonal regulation of food intake. Physiol Rev 85:1131–1158
56. Suen PM, Zou C, Zhang YA, Lau TK, Chan J, Yao KM, Leung PS (2008) PDZ-domain containing-2 (PDZD2) is a novel factor that affects the growth and differentiation of human fetal pancreatic progenitor cells. Int J Biochem Cell Biol 40:789–803
57. Townsend T (2000) A decade of diabetes research and development. Int J Diabetes Metab 8:88–92
58. Vaghasiya JD, Sheth NR, Bhalodia YS, Jivani NP, Shailesh M, Jivani N (2010) Exenatide protects renal ischemia reperfusion injury in type 2 diabetes mellitus. Int J Diabetes Dev Ctries 30(4):217–225
59. Vetter ML, Cardillo S, Rickels MR, Iqbal N (2009) Narrative review: effect of bariatric surgery on type 2 diabetes mellitus. Ann Intern Med 150:94–103
60. Whalley NM, Pritchard LE, Smith DM (2011) White A. Processing of proglucagon to GLP-1 in pancreatic α-cells: is this a paracrine mechanism enabling GLP-1 to act on β-cells? J Endocrinol 211:99–106
61. Wideman RD, Kieffer TJ (2004) Glucose-dependent insulinotropic polypeptide as a regulator of beta cell function and fate. Horm Metab Res 36:782–786
62. Wong ML, Medrano JF (2005) Real-time PCR for mRNA quantitation. BioTech 39:75–85